SCHEMBL13637232

SCHEMBL13637232

Cc1ccc(-c2ncccn2)c(N)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 5/20 0.42
NOS2 P35228 5/20 0.42
NOS1 P29475 1/20 0.42
NSD2 O96028 1/20 0.37
G6PD P11413 1/20 0.37
DNMT1 P26358 1/20 0.37
HCRTR1 O43613 2/20 0.36
HCRTR2 O43614 2/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.36
HSD17B10 Q99714 2/20 0.35
GRM5 P41594 1/20 0.34
BRAF P15056 1/20 0.34
PIK3CA P42336 1/20 0.34
KDM4E B2RXH2 3/20 0.33
S100A4 P26447 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7910798 0.79 KDM4E (0.46) HPGDRAB9ANPC1TP53SMN1; SMN2
SCHEMBL10262761 0.79 BRAF (0.45) NOS3NOS2NOS1HCRTR1HCRTR2
SCHEMBL27728631 0.78 DHODH (0.38) HCRTR1HCRTR2HPGDRAB9ANPC1
SCHEMBL10161000 0.76 NOS2 (0.38) NOS3NOS2NOS1LMNAKDM4E
SCHEMBL7901595 0.75 HCRTR1 (0.37) HCRTR1HCRTR2POLB
SCHEMBL8306873 0.73 ALDH1A1 (0.53) NOS3NOS2HPGDRAB9ANPC1
SCHEMBL14208119 0.73 NOS2 (0.41) NOS3NOS2NOS1TP53SMN1; SMN2
SCHEMBL26179657 0.72 NOS2 (0.48) NOS3NOS2NOS1LMNAPIK3CA
SCHEMBL7907148 0.72 CCR1 (0.58) NOS3NOS2NSD2G6PDDNMT1
SCHEMBL10130942 0.72 ALDH1A1 (0.39) NOS3NOS2NOS1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017178344-A1 NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-19 WO disclosed
US-7622452-B2 C-9 alkenylidine bridged macrolides ENANTA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES ENANTA PHARMACEUTICALS, INC. 2008-05-22 US disclosed
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 NOS3 1409/4885NOS2 1291/4885NOS1 1244/4885
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES CYP2C9, CCR9, DPP9 NOS3 1721/4885NOS2 1681/4885NOS1 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.